Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 04, 2005. The report serves as a notification of changes in directors' interests in the company's Ordinary Shares, specifically regarding transactions within the SmithKline Beecham Employee Benefit Trust.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction details rather than financial performance metrics.
Material Changes
On April 29, 2005, the following transactions occurred within the Employee Benefit Trust, notified to the company on May 04, 2005:
- Bonus Investment Plan: 647 Ordinary shares were sold at £13.251 per share, and 2,346 Ordinary shares were transferred to a participant.
- Annual Investment Plan: 1,439 Ordinary shares were sold at £13.251 per share, and 92,133 Ordinary shares were transferred to participants.
Outlook, Risks, and Management Commentary
The filing contains no guidance, outlook, or management commentary regarding future business performance. It notes that the Trust is a discretionary fund for non-US employees and former employees. Director Julian Heslop is identified as having an interest in the shares held in the fund, similar to other eligible employees. No specific risks or contingencies are disclosed in this report.
Investor Verification Points
- Verify the total number of shares held by the SmithKline Beecham Employee Benefit Trust to assess the scale of these transactions relative to the trust's total holdings.
- Confirm the specific ownership percentage of Director Julian Heslop within the Trust to understand the magnitude of his indirect interest.
- Review the company's Form 20-F for comprehensive financial data, as this Form 6-K does not contain financial statements.